[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Shattuck Labs Inc (STTK)

Shattuck Labs Inc (STTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 379,571
  • Shares Outstanding, K 76,681
  • Annual Sales, $ 1,000 K
  • Annual Income, $ -48,810 K
  • EBIT $ -52 M
  • EBITDA $ -48 M
  • 60-Month Beta 1.08
  • Price/Sales 363.47
  • Price/Cash Flow N/A
  • Price/Book 3.74

Options Overview Details

View History
  • Implied Volatility 159.29% (-133.33%)
  • Historical Volatility 106.51%
  • IV Percentile 13%
  • IV Rank 12.22%
  • IV High 978.35% on 01/15/26
  • IV Low 45.22% on 10/16/25
  • Expected Move (DTE 28) 0.48 (9.79%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 453
  • Volume Avg (30-Day) 642
  • Put/Call OI Ratio 1.43
  • Today's Open Interest 5,529
  • Open Int (30-Day) 2,097
  • Expected Range 4.47 to 5.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.14
  • Number of Estimates 4
  • High Estimate $-0.10
  • Low Estimate $-0.18
  • Prior Year $-0.24
  • Growth Rate Est. (year over year) +41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.33 +48.65%
on 06/08/26
6.39 -22.54%
on 05/22/26
-1.02 (-17.09%)
since 05/18/26
3-Month
3.33 +48.65%
on 06/08/26
8.33 -40.58%
on 04/20/26
-1.09 (-18.05%)
since 03/18/26
52-Week
0.71 +595.22%
on 08/12/25
8.33 -40.58%
on 04/20/26
+3.98 (+408.00%)
since 06/18/25

Most Recent Stories

More News
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development...

STTK : 4.95 (+4.43%)
Shattuck Labs, Inc. Announces Proposed Public Offering

AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development...

STTK : 4.95 (+4.43%)
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class...

STTK : 4.95 (+4.43%)
Shattuck Labs Announces Phase 1 Results for SL-325

Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of 1...

STTK : 4.95 (+4.43%)
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class...

STTK : 4.95 (+4.43%)
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights

Phase 1 clinical trial of SL-325 enrollment complete; data expected in the second quarter of 2026 – Phase 2 clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the...

STTK : 4.95 (+4.43%)
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights

Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 – Phase 2 clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third quarter...

STTK : 4.95 (+4.43%)
Shattuck Labs Announces Participation in Upcoming March Investor Conferences

AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class...

STTK : 4.95 (+4.43%)
Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium

AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting...

STTK : 4.95 (+4.43%)
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development...

STTK : 4.95 (+4.43%)

Business Summary

Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North...

See More

Key Turning Points

3rd Resistance Point 5.46
2nd Resistance Point 5.27
1st Resistance Point 5.11
Last Price 4.95
1st Support Level 4.76
2nd Support Level 4.57
3rd Support Level 4.41

See More

52-Week High 8.33
Fibonacci 61.8% 5.42
Last Price 4.95
Fibonacci 50% 4.52
Fibonacci 38.2% 3.62
52-Week Low 0.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.